Journal of Infection最新文献

{"title":"Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial","authors":"E. Kelly ,&nbsp;M. Greenland ,&nbsp;P. de Whalley ,&nbsp;G.C. Macaulay ,&nbsp;P.K. Aley ,&nbsp;E. Plested ,&nbsp;S. Koleva ,&nbsp;J. Cotton ,&nbsp;J. Kinch ,&nbsp;T. Madupuri ,&nbsp;R.C. Read ,&nbsp;M. Ramsay ,&nbsp;C. Cameron ,&nbsp;D.P.J. Turner ,&nbsp;P. Heath ,&nbsp;P. Connor ,&nbsp;K. Cathie ,&nbsp;S.N. Faust ,&nbsp;I. Banerjee ,&nbsp;K. Man ,&nbsp;X. Liu","doi":"10.1016/j.jinf.2025.106663","DOIUrl":"10.1016/j.jinf.2025.106663","url":null,"abstract":"<div><h3>Background</h3><div>The emergence of SARS-CoV2 variants combined with waning vaccine-induced immunity and breakthrough infections has highlighted the need for booster doses to maintain protection against SARS-CoV2 infection and disease.</div></div><div><h3>Methods</h3><div>Com-COV3 was a phase II, multicentre, randomised controlled trial, recruiting across 11 UK sites from June 2022 to June 2023, with follow-up visits to February 2024. Healthy 12–15-year-olds who had received a two-30 μg dose BNT162b2 primary regimen at least 90 days previously were randomised 1:1:1:1:1 to receive either BNT162b2 30 μg, BNT162b2 10 μg (adult vaccine formulation), BNT162b2 10 μg (paediatric formulation), NVXCoV2373, or Meningococcal B vaccine (control). The primary objective was to determine if SARS-CoV-2 anti-spike antibody following a 10 μg dose of the adult formulation of BNT162b2 was non-inferior to the paediatric formulation at 28 days post-third vaccination. The last five participants were randomised using a 1:3:3:1:1 ratio to prioritise recruitment to the study groups required for the co-primary endpoint. Although recruitment ceased early, the sample size required to fulfil the primary objective was met.</div></div><div><h3>Findings</h3><div>281 participants were recruited (mean age 14 years old, 57% female). Adverse reactions were mostly mild-to-moderate. Local reactogenicity was mildest following NVXCoV2373. Frequency of adverse events was similar for both full dose and fractional dose BNT162b2 groups. Four serious adverse events occurred: three in the paediatric and one in the adult 10 μg BNT162b2 group. Immunogenicity of 10 μg BNT162b2 (adult) was both non-inferior and superior to that of 10 μg BNT162b2 (paediatric); adjusted geometric mean ratio (aGMR) anti-spike IgG 1.50 (one-sided 95% CI 1.25 to ∞). Compared with 30 μg BNT162b2, anti-spike IgG at day 28 post-third dose were similar in the 10 μg BNT162b2 (adult) group [aGMR 0.93 (95% CI 0.75–1.14)] and significantly lower in the 10 μg BNT162b2 (paediatric) [aGMR 0.64 (95% CI 0.52–0.78)] and NVXCoV2373 [aGMR 0.77 (95% CI 0.63–0.95)] groups. Compared with 30 μg BNT162b2, levels of neutralising antibodies against Omicron BA.5 and XBB.15 were similar across vaccine groups.</div></div><div><h3>Interpretation</h3><div>All booster regimens evaluated elicited a robust immune response. 10 μg fractional adult BNT162b2 vaccine demonstrated similar immunogenicity compared with 30 μg BNT162b2 and superior immunogenicity compared with 10 μg paediatric BNT162b2 vaccine. Fractional doses of the adult BNT162b2 vaccine are an alternative to the paediatric formulation for booster campaigns in adolescents.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"92 1","pages":"Article 106663"},"PeriodicalIF":11.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145670432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpretable machine learning based comorbidity specific mortality risk score for bloodstream infections","authors":"Chen Cui ,&nbsp;Jinyi Zhao ,&nbsp;Fei Mu ,&nbsp;Dahua Wang ,&nbsp;Yamei Li ,&nbsp;Meng Tang ,&nbsp;Kexin Sun ,&nbsp;Rui Gong ,&nbsp;Zhen Yan ,&nbsp;Jingwen Wang","doi":"10.1016/j.jinf.2025.106656","DOIUrl":"10.1016/j.jinf.2025.106656","url":null,"abstract":"<div><h3>Objectives</h3><div>Bloodstream infections (BSI) are a leading cause of sepsis, necessitating early risk stratification during the critical window for effective management. We aimed to develop a model that leverages early-phase clinical data to predict 28-day mortality by integrating longitudinal trends and addressing comorbidity-driven heterogeneity.</div></div><div><h3>Methods</h3><div>The BSI Heterogeneity Score (BHScore) was developed using machine learning on longitudinal clinical data (first 7 days post-culture) from 2524 BSI patients at Xijing Hospital. The model uses interpretable methods to establish comorbidity-stratified thresholds (global, renal disease, liver disease, metastatic malignancy) to enhance prediction accuracy.</div></div><div><h3>Results</h3><div>The BHScore demonstrated superior discriminatory performance (area under the receiver operating characteristic curve: 0.81–0.91) and temporal stability compared to established scores including the Sequential Organ Failure Assessment (SOFA), representing an improvement of 10% to 25%. Our analysis revealed that coagulation biomarkers have greater prognostic significance in the malignancy subgroup, inflammatory thresholds are more sensitive in the liver disease subgroup, and urea levels exhibit U-shaped mortality curves in the renal disease subgroup. To support clinical application, a freely accessible web tool has been developed.</div></div><div><h3>Conclusions</h3><div>The BHScore enables the early identification of high-risk BSI patients with diverse comorbidities using straightforward clinical indicators, facilitating timely and targeted interventions to reduce mortality.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"91 6","pages":"Article 106656"},"PeriodicalIF":11.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145543714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The epidemic pattern of a chikungunya outbreak in China exhibits a three-stage migratory trend","authors":"Jiajia Zhang ,&nbsp;Juncheng Cai ,&nbsp;Changhai Liu ,&nbsp;Marco Túlio Dos Santos Costa ,&nbsp;Tao Ren ,&nbsp;Libin Chen","doi":"10.1016/j.jinf.2025.106646","DOIUrl":"10.1016/j.jinf.2025.106646","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"91 6","pages":"Article 106646"},"PeriodicalIF":11.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipoarabinomannan (LAM) for the diagnosis of tuberculosis from sputum","authors":"Steffen Pichlo,&nbsp;Patricia Sanchez Carballo,&nbsp;Maja Reimann,&nbsp;Nika Zielinski,&nbsp;Yassir Adam Shuaib,&nbsp;Niklas Köhler,&nbsp;Sönke Andres,&nbsp;Jan Heyckendorf ,&nbsp;Barbara Kalsdorf,&nbsp;Ioana D. Olaru ,&nbsp;Helmut J.F. Salzer ,&nbsp;Christoph Lange","doi":"10.1016/j.jinf.2025.106662","DOIUrl":"10.1016/j.jinf.2025.106662","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"91 6","pages":"Article 106662"},"PeriodicalIF":11.9,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145566179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving pneumococcal epidemiology and vaccine impact in the Netherlands, 2004–2024: Carriage and invasive disease","authors":"Maurits T. Wulffraat ,&nbsp;Nelleke G. van de Weijer ,&nbsp;Alienke J. Wijmenga-Monsuur ,&nbsp;Paul Badoux ,&nbsp;Anneke Steens ,&nbsp;Debbie Smit ,&nbsp;Rob Mariman ,&nbsp;Krzysztof P. Trzciński ,&nbsp;Nina M. van Sorge ,&nbsp;Nynke Y. Rots ,&nbsp;Marianne A. van Houten","doi":"10.1016/j.jinf.2025.106658","DOIUrl":"10.1016/j.jinf.2025.106658","url":null,"abstract":"<div><h3>Objectives</h3><div>Since pneumococcal conjugate vaccines (PCVs) were introduced into the Dutch childhood National Immunization Program in 2006, colonization and invasive disease of <em>Streptococcus pneumoniae</em> have declined, alongside shifts in serotype prevalence towards non-vaccine serotypes (NVTs). To monitor changes and estimate the added value of higher-valent PCVs, serotype-specific carriage, invasive pneumococcal disease (IPD) and invasive disease potential were analyzed.</div></div><div><h3>Methods</h3><div>During the winters of 2018/2019 and 2022/2023 pneumococcal carriage was determined among 24-month-old children and parents, and compared to carriage studies from 2005 to 2016. IPD data from Dutch surveillance (2004–2024) were included. Pneumococcal isolates were serotyped using agglutination and Quellung. Serotype-specific disease potential determined as odds ratios (OR) for IPD versus carriage.</div></div><div><h3>Results</h3><div>Pneumococcal carriage in children decreased from 66% in 2005 to 49% in 2018/2019 and 46% in 2022/2023. In 2022/2023, 29% of children carried NVTs, followed by PCV20- (11%), PCV13- (4%), PCV15- (2%) and PCV10- (0%) specific serotypes. Among parents, carriage declined from 17% in 2005 to 2% by 2022/2023. IPD incidence increased from 6·7 to 8·4 per 100,000 children under 5 years between 2018–2020 and 2022–2024, predominantly caused by an increase in serotype 19A. Serotypes 8 and 3 have the highest invasive disease potential.</div></div><div><h3>Conclusions</h3><div>This study shows stabilized pneumococcal carriage from 2018 to 2023 with low invasive disease potential for common serotypes, except for serotype 19A. However, rising IPD incidence from other non-vaccine serotypes highlights the need for higher-valency vaccines. The newly introduced PCV15 covers 58% of IPD cases, while PCV20 could cover 73%.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"91 6","pages":"Article 106658"},"PeriodicalIF":11.9,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasmodium falciparum gene expression signatures and antibody profiling implicate the fikk, phist, and surf multigene families in severe malaria syndromes","authors":"Bryan E. Cummings ,&nbsp;Emily M. Stucke ,&nbsp;Drissa Coulibaly ,&nbsp;Jonathan G. Lawton ,&nbsp;Rafal S. Sobota ,&nbsp;Abdoulaye Kassoum Kone ,&nbsp;Bourama Kane ,&nbsp;Bouréima Guindo ,&nbsp;Bourama Tangara ,&nbsp;Mody Sissoko ,&nbsp;Fayçal Maiga ,&nbsp;Karim Traore ,&nbsp;Aichatou Diawara ,&nbsp;Amidou Traore ,&nbsp;Ali Thera ,&nbsp;Antoine Dara ,&nbsp;Amadou Niangaly ,&nbsp;Modibo Daou ,&nbsp;Issa Diarra ,&nbsp;Youssouf Tolo ,&nbsp;Mark A. Travassos","doi":"10.1016/j.jinf.2025.106655","DOIUrl":"10.1016/j.jinf.2025.106655","url":null,"abstract":"<div><div><em>Plasmodium falciparum</em> is the most virulent <em>Plasmodium</em> species, responsible for the life-threatening severe malaria syndromes of cerebral malaria and severe malarial anemia. In a Mali case-control study, we determined parasite gene expression in cerebral malaria, severe malarial anemia, and concurrent disease featuring both syndromes by comparing RNA-seq data from severe malaria cases to matched uncomplicated malaria controls with or without a history of cerebral malaria. While severe malarial anemia comparisons produced comparatively low levels of differential expression, the comparisons of cerebral malaria and concurrent disease yielded significant differential expression of multigene families (<em>fikk</em>, <em>phist</em>, and <em>surf</em>) implicated in processes that escalate disease severity, such as cytoadherence and erythrocytic remodeling. We probed custom microarrays featuring these antigens with acute and convalescent sera. Children with severe malaria developed antibody responses to subsets of these proteins following severe malaria infection, suggesting exposure to these antigens during illness and their potential as targets in the development of natural protective immunity against severe malaria. Our findings address knowledge gaps surrounding parasite gene expression in severe malarial anemia. Further, these results broaden the scope of multigene families implicated in severe malaria pathogenesis and underscore the utility of transcriptome-wide approaches for a comprehensive understanding of severe disease, particularly when developing therapeutics or vaccines.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"91 6","pages":"Article 106655"},"PeriodicalIF":11.9,"publicationDate":"2025-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term impact of nirsevimab on prevention of respiratory syncytial virus infection using a real-world global database","authors":"Taito Kitano ,&nbsp;Shinya Tsuzuki ,&nbsp;Haruhisa Fukuda ,&nbsp;Sayaka Yoshida","doi":"10.1016/j.jinf.2025.106652","DOIUrl":"10.1016/j.jinf.2025.106652","url":null,"abstract":"<div><h3>Objective</h3><div>The preventive effect of nirsevimab, a long-acting monoclonal antibody, on infants with respiratory syncytial virus (RSV) infection beyond six months has rarely been evaluated. The objective of this study was to evaluate the preventive effects of nirsevimab beyond 6 months after RSV infection using a global database.</div></div><div><h3>Methods</h3><div>This was a multi-centre retrospective study using a global database (TriNetX). The participants were children under 24 months of age who required nucleic acid testing for RSV between July 2023 and June 2025. Children who received the last dose of nirsevimab within 6 months, between 6 and 11 months, and beyond 12 months were compared with those who did not receive any nirsevimab dose by epidemic season after propensity score matching.</div></div><div><h3>Results</h3><div>A total of 4627, 861, and 532 children aged &lt;24 months who received nirsevimab within 6 months, between 6 and 11 months, and beyond 12 months before RSV testing, respectively, and 210,626 children who did not receive any nirsevimab were identified. Compared with those who did not receive nirsevimab, the odds ratios (OR) of a positive RSV test result among those who received nirsevimab within 6 months, between 6 and 11 months, and beyond 12 months before testing were 0.49 [95% confidence interval (CI) 0.42, 0.57] (p&lt;0.001), 0.67 [0.48, 0.94] (p&lt;0.020), and 1.21 [0.89, 1.65] (p=0.234) in the last epidemic season, respectively.</div></div><div><h3>Conclusion</h3><div>This study indicated that the preventive effect of nirsevimab against RSV infection was maintained for up to 12 months following administration, whereas a preventive effect beyond 12 months was not observed. The results of this study need to be interpreted with caution owing to some important limitations.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"91 6","pages":"Article 106652"},"PeriodicalIF":11.9,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145483615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibodies to female Aedes albopictus salivary proteins promote dengue virus infection with salivary proteins","authors":"Na Liu ,&nbsp;Yanmei Li ,&nbsp;Zhouyu Wu ,&nbsp;Wenfei Qiao ,&nbsp;Qianqian Zheng ,&nbsp;Jing Zhuo ,&nbsp;Yangzi Liu ,&nbsp;Mengjie Lin ,&nbsp;Ying Fu ,&nbsp;Jiugang Zhao","doi":"10.1016/j.jinf.2025.106638","DOIUrl":"10.1016/j.jinf.2025.106638","url":null,"abstract":"<div><h3>Objective</h3><div>Mosquito saliva can facilitate arboviral infection, yet whether host antibodies to salivary proteins modulate dengue virus (DENV) infection remains unclear. To test whether antibodies induced by <em>Aedes albopictus</em> salivary proteins (AaSP) enhance DENV infection when AaSP is present.</div></div><div><h3>Methods</h3><div>We used RAW264.7 cells and <em>BALB/c</em> mice; generated anti-AaSP antisera; co-incubated DENV with AaSP; quantified NS1 mRNA, envelope protein, and cytopathic effects (CPE); and assessed tissue pathology. We compared female- versus male-derived AaSP and antisera, performed proteomics, tested recombinant Obp1 and D7L, purified IgG, and evaluated papain digestion and Fcγ receptor (anti-CD16/32, clone 2.4G2) blockade.</div></div><div><h3>Results</h3><div>Antiserum with AaSP increased DENV infection in vitro and aggravated pathology in vivo. Repeated <em>A. albopictus</em> bites induced anti-AaSP antibodies and led to more severe disease after infection with AaSP-preincubated virus. Only female-AaSP antisera enhanced infection; proteomics showed sex-distinct salivary profiles. Obp1 and D7L enhanced infection with antiserum. Purified IgG reproduced the increase, which was lost after papain digestion or FcγR blockade.</div></div><div><h3>Conclusion</h3><div>Anti-AaSP IgG can increase DENV infection in the presence of AaSP. These findings add to understanding of DENV pathogenesis and may help inform future exploration of prevention targets.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"91 5","pages":"Article 106638"},"PeriodicalIF":11.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145474436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between pre-diagnostic fluoroquinolone exposure and possible acquired fluoroquinolone resistance in Mycobacterium tuberculosis in Shanghai: An EHR-based case-control study using whole-genome sequencing","authors":"Yangyi Zhang ,&nbsp;Danni Li ,&nbsp;Jiazhen Liu ,&nbsp;Yuan Jiang ,&nbsp;Xin Shen ,&nbsp;Biao Xu","doi":"10.1016/j.jinf.2025.106648","DOIUrl":"10.1016/j.jinf.2025.106648","url":null,"abstract":"<div><h3>Objectives</h3><div>Fluoroquinolones (FQ) are one of the most prescribed broad-spectrum antibiotics and a cornerstone of tuberculosis (TB) treatment. TB patients may have had FQ resistance before treatment initiation. However, the association between pre-diagnostic FQ exposure and acquired FQ-resistant TB remains unclear.</div></div><div><h3>Methods</h3><div>A case-control study was conducted among all pulmonary TB patients in Shanghai during 2022–2023. Cases were TB patients who had possible acquired FQ resistance identified through whole-genome sequencing (WGS), while controls were FQ susceptible patients. Pre-diagnostic FQ prescriptions were extracted from the Shanghai Electronic Health Record (EHR) platform.</div></div><div><h3>Results</h3><div>Among 3496 patients, 7.4% had FQ-resistant TB, with 93.5% (243/260) phylogenetically inferred as possible acquired resistance. Multivariate analysis revealed FQ exposure was the strongest predictor of possible acquired FQ resistance with an aOR of 4.31 for a single prescription and 13.18 for multiple prescriptions. A nonlinear dose-response relationship between resistance probability and prescription number was found. Most prescriptions to cases were from non-TB-designated tertiary hospitals for non-TB respiratory diseases, with an exposure interval of ≥61 days prior to TB diagnosis.</div></div><div><h3>Conclusion</h3><div>Acquired resistance dominates FQ resistance in Shanghai TB patients. The dose-response relationship between pre-diagnostic FQ exposure and possible acquired resistance underscores the need for judicious FQ use.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"91 5","pages":"Article 106648"},"PeriodicalIF":11.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global emergence and polycentric evolution of invasive Streptococcus pyogenes M1UK lineage","authors":"Hizbullah Khan ,&nbsp;Haoyuan Lun ,&nbsp;Guangxian Xu ,&nbsp;Kaisong Huang","doi":"10.1016/j.jinf.2025.106653","DOIUrl":"10.1016/j.jinf.2025.106653","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"91 5","pages":"Article 106653"},"PeriodicalIF":11.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145472526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}